MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.220
-0.010
-0.31%
After Hours: 3.100 -0.12 -3.73% 17:27 04/02 EDT
OPEN
3.240
PREV CLOSE
3.230
HIGH
3.420
LOW
3.120
VOLUME
53.31K
TURNOVER
--
52 WEEK HIGH
9.37
52 WEEK LOW
3.020
MARKET CAP
68.11M
P/E (TTM)
-3.3234
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GLMD stock price target is 21.94 with a high estimate of 34.00 and a low estimate of 10.00.

EPS

GLMD News

More
  • Edited Transcript of GLMD earnings conference call or presentation 12-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 03/26 21:06
  • Stifel Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $25
  • Benzinga · 03/13 13:53
  • B. Riley FBR Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $11
  • Benzinga · 03/13 11:37
  • Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 19:47

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About GLMD

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
More

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.